GLP1R and early-onset autosomal dominant Alzheimer disease: The potential neuroprotective properties of GLP-1R agonists have also been demonstrated in clinical trials, with Novo Nordisk currently running a phase III clinical trial of oral semaglutide as a potential treatment option for Alzheimer’s disease in the announced EVOKE trial program (NCT04777409, NCT04777396).